Status | In progress |
Technology type | Medicine |
Decision | Selected |
Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
Process | STA Standard |
ID number | 3990 |
Provisional Schedule
Committee meeting: 1 | 11 July 2024 |
Expected publication | 18 September 2024 |
Project Team
Project lead | Jeremy Powell |
Email enquiries
- If you have any queries please email TAteam2@nice.org.uk
External Assessment Group | Bristol Technology Assessment Group, University of Bristol |
Stakeholders
Companies sponsors | Plusultra (sirolimus) |
Others | Department of Health and Social Care |
NHS England | |
Patient carer groups | Changing Faces |
Genetic Alliance UK | |
Gene People | |
Lets Face It | |
South Asian Health Foundation | |
Specialised Healthcare Alliance | |
Tuberous Sclerosis Association | |
Professional groups | Association of Genetic Nurses & Counsellors |
British Association of Dermatologists | |
British Dermatological Nursing Group | |
British Geriatrics Society | |
British Society for Gene and Cell Therapy | |
British Society for Genetic Medicine | |
General Medical Council | |
Neonatal and Paediatric Pharmacists Group | |
Primary Care Dermatology Society | |
Royal College of General Practitioners | |
Royal College of Nursing | |
Royal College of Pathologists | |
Royal College of Physicians | |
Royal Pharmaceutical Society | |
Royal Society of Medicine | |
UK Clinical Pharmacy Association | |
UK Genetic Testing Network | |
UK Kidney Association | |
Associated public health groups | Public Health Wales |
UK Health Security Agency | |
Comparator companies | none |
General commentators | All Wales Therapeutics and Toxicology Centre |
Allied Health Professionals Federation | |
Board of Community Health Councils in Wales | |
British National Formulary | |
Care Quality Commission | |
Cell and Gene Therapy Catapult | |
Department of Health, Social Services and Public Safety for Northern Ireland | |
Great Ormond Street Hospital | |
Healthcare Improvement Scotland | |
Medicines and Healthcare products Regulatory Agency | |
National Association of Primary Care | |
National Pharmacy Association | |
NHS Confederation | |
Paediatric Neurodisability TSC Clinic, Alder Hey Children’s Hospital | |
Paediatric Neurology TSC Clinic, University Hospitals Bristol | |
Scottish Medicines Consortium | |
TSC Team, Children’s Centre, Royal United Hospital Bath | |
Welsh Government | |
Welsh Health Specialised Services Committee | |
Relevant research groups | British Skin Foundation |
Cochrane Cystic Fibrosis & Genetic Disorders Group | |
Cochrane Skin Group | |
Cochrane UK | |
Dermatrust | |
Genomics England | |
MRC Clinical Trials Unit | |
National Institute for Health Research |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
15 December 2023 | Invitation to participate |
15 December 2023 | At the company's request, the appraisal has restarted. |
18 October 2023 | Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during late November 2023 when we will write to you about how you can get involved. |
06 June 2023 | Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. The planned Committee meeting will not take place. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. |
24 October 2022 (14:00) | Scoping workshop |
16 August 2022 - 14 September 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
16 August 2022 | In progress. Scoping commenced |
28 January 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual